

Datasheet for KOA0378

Human TNFRSF17 - BCMA ELISA Kit**Overview**

| | |
|----------------------|--|
| Description: | Human TNFRSF17/BCMA AccuSignal ELISA Kit - KOA0378 |
| Item No.: | KOA0378 |
| Size: | 1 Kit |
| Applications: | ELISA |
| Reactivity: | Human |
| Range: | 31.2 pg/ml - 2000 pg/ml |

Product Details

| | |
|----------------------------|--|
| Background: | TNFRSF17(Tumor necrosis factor receptor superfamily member 17), also called BCMA, is a protein that in humans is encoded by the TNFRSF17 gene. The protein encoded by this gene is a member of the TNF-receptor superfamily and is mapped to 16p13.13. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor(ligand) superfamily, member 13b(TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. |
| Synonyms: | B cell maturation antigen, B cell maturation factor, B cell maturation protein, B-cell maturation protein, BCM, BCMA, CD 269, CD269, CD269 antigen, TNFRSF 17, TNFRSF17, TNFR17_HUMAN, Tumor necrosis factor receptor member 17, Tumor necrosis factor receptor superfamily member 17 |
| Detection Kit Type: | ELISA Kit |
| Detection Range: | 31.2 pg/ml - 2000 pg/ml |
| Sensitivity: | <10 pg/ml |

Target Details

| | |
|--------------------|---|
| Gene Name: | TNFRSF17 |
| Reactivity: | Human |
| Immunogen: | Expression system for standard: NSO; Immunogen sequence: M1-A54 |

Purity/Specificity: Natural and recombinant human TNFRSF17. There is no detectable cross-reactivity with other relevant proteins.

Relevant Links:

- [UniProtKB - Q02223](#)
- [NCBI - NP_001183.2](#)
- [GeneID - 608](#)
- [KOA0378 Protocol](#)

Application Details

Tested Applications: ELISA

Application Note: Useful in Sandwich ELISA for Quantitative Detection of Antigen. Aliquot 0.1ml per well of the 2000pg/ml, 1000pg/ml, 500pg/ml, 250pg/ml, 125pg/ml, 62.5pg/ml, 31.2pg/ml human TNFRSF17 standard solutions into the precoated 96-well plate. Add 0.1ml of the sample diluent buffer into the control well (Zero well). Add 0.1ml of each properly diluted sample of human cell culture supernates, serum or plasma(heparin, EDTA) to each empty well. It is recommended that each human TNFRSF17 standard solution and each sample be measured in duplicate.

Assay Dilutions: All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.

ELISA: 31.2 pg/ml-2000pg/ml

Other: DOE,
2-8° C -08/16/2023
-20° C -02/14/2024

Formulation

Concentration: 1 kit

Anticoagulant: Heparin Sodium


Shipping & Handling

Shipping Condition: Wet Ice

Storage Condition: Store vials at 4°C prior to opening. Centrifuge product if not completely clear after standing at room temperature. This product is stable for 6 months at 4°C as an undiluted liquid. Dilute only prior to immediate use. For extended storage freeze at -20°C or below for 12 months. Avoid cycles of freezing and thawing.

Expiration: See kit insert for complete instructions.

Images



ELISA

Human TNFRSF17/BCMA AccuSignal ELISA Kit standard curve. Assay Range: 31.2pg/ml-2000pg/ml. Sensitivity: <10pg/ml.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.